BackCERo Therapeutics Holdings - Warrants (13/02/2029) Overview
CERo Therapeutics Holdings Inc. - Warrants (13/02/2029)

CERo Therapeutics Holdings - Warrants (13/02/2029) Return on Equity

Latest ROE for CERo Therapeutics Holdings - Warrants (13/02/2029): 416.3% — see history and peer comparisons.

Get informed when a big investor buys or sells

+ Follow

ROE

416.30%

Return on Equity

416.30%

Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.

ROE (Comparison Companies)

Loading

ROE History

Loading

ROE Comparison

Loading

CERo Therapeutics Holdings - Warrants (13/02/2029) (CEROW) FAQ

CERo Therapeutics Holdings - Warrants (13/02/2029) posts a ROE of 416.3%. That is above the sector sector average of -5.68%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

For its sector stocks, a ROE near -5.68% is typical. CERo Therapeutics Holdings - Warrants (13/02/2029)'s 416.3% is higher that level. That is roughly 7425.2% above the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

CERo Therapeutics Holdings - Warrants (13/02/2029)'s ROE moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is 416.3%; use YoY and peer views to separate noise from signal.

Context for CEROW's ROE usually means three checks: (1) trend versus prior periods, (2) level versus peers (average -5.68%), and (3) consistency with growth and profitability. This page covers the first two; CERo Therapeutics Holdings - Warrants (13/02/2029)'s other metric pages and overview cover the third.